Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00346125 · ClinicalTrials.gov registry record · NA
PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 70
- Enrollment target
NCT00346125 is a NA study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 70 participants.
The verdict
NCT00346125, a NA study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
Study Summary
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) scan and computated tomography (CT) scan, may help doctors predict a patient's response to treatment and may help plan the best treatment. Drugs used in chemotherapy, such as doxorubicin and ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This clinical trial is studying how well PET scan combined with CT scan predicts response in patients undergoing chemotherapy and surgery for soft tissue sarcoma.
Interventions
- DRUG pegylated liposomal doxorubicin hydrochloride
- PROCEDURE conventional surgery
- DRUG ifosfamide
- DRUG doxorubicin hydrochloride
- BIOLOGICAL pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2006-04-10 |
| Est. Completion | 2022-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00346125
The ClinicalTrials.gov registry entry for NCT00346125 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which pegylated liposomal doxorubicin hydrochloride is the first listed.
NCT00346125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00346125 about?
NCT00346125 is a clinical study titled "PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma". RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) scan and computated tomography (CT) scan, may help doctors predict a patient's response to treatment and may help plan the best treatment. Drugs used in chemotherapy, such as doxorubicin and ifosfamide, work in different wa...
What is the current status of trial NCT00346125?
This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2006-04-10. Estimated completion is 2022-07.
What interventions are being tested in trial NCT00346125?
The interventions under investigation include: pegylated liposomal doxorubicin hydrochloride (DRUG), conventional surgery (PROCEDURE), ifosfamide (DRUG), doxorubicin hydrochloride (DRUG), pegfilgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00346125?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.